Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00312026
Status:
COMPLETED
Last Update Posted:
2017-02-15
First Post:
2006-04-05
Brief Title:
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands andor Feet
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase IV Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of 10 mgkg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis Involving the Hands andor Feet
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase IV randomized double-blind placebo-controlled study to evaluate the safety and efficacy of SC efalizumab in adult patients 18 years of age and older with chronic moderate to severe plaque psoriasis involving the hands andor feet who have had no previous exposure to efalizumab The study will consist of a screening period a treatment period and an observation period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None